Clinical and Pathologic Studies in Non-Hodgkin’s Lymphoma Patients Receiving Antibody Treatment
Overview
To characterize the molecular and cell biology of the tumor cells in lymphoma. The mechanism of monoclonal antibody treatment by rituximab or epratuzumab will also be examined.
Full Title of Study: “Le20: Clinical and Pathologic Studies in Non-Hodgkin’s Lymphoma Patients Receiving Antibody Treatment”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Study Primary Completion Date: June 2007
Interventions
- Drug: Rituximab
- Drug: Epratuzumab
Clinical Trial Outcome Measures
Primary Measures
- To characterize the molecular and cell biology of the tumor cells in lymphoma.
- Time Frame: 6 months
Participating in This Clinical Trial
Inclusion Criteria
Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Stanford University
- Collaborator
- Amgen
- Provider of Information About this Clinical Study
- Wen-Kai Weng, Stanford University School of Medicine
- Overall Official(s)
- Wen-Kai Weng, Principal Investigator, Stanford University
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.